The Q-REstrain therapy RGCC International offers is an innovative treatment using RNA interference (RNAi) technology. This advanced approach targets cancer cells, viruses, or microorganisms such as Lyme disease with exceptional precision, disrupting their ability to reproduce and survive. Here's an overview of the therapy:

How Q-REstrain Works

1. RNA Interference Technology:
   • The therapy utilizes RNA molecules to block essential biological processes within target cells (e.g., cancer cells, viruses, or pathogens).
   • This disruption prevents the cells or organisms from completing their life cycle, halting their replication.
2. Target-Specific Action:
   • Q-REstrain achieves 98% specificity, targeting only the genes of cancerous or pathogenic cells without affecting healthy human cells.
3. Long-Lasting Effect:
   • Administered as a single-dose intravenous infusion, Q-REstrain remains active in the body for up to six months, inhibiting replication and metabolism of the target cells.

Therapeutic Goals

• Eliminate existing cancer cells or pathogens such as viruses or Lyme bacteria.
• Minimize the burden of disease without damaging healthy cells.

Key Applications

• Cancer Treatment: Effective for hematologic (blood) and solid tumors, particularly in early stages or cases with small cancer burdens.
• Pathogen Treatment: Suitable for viruses and conditions like Lyme disease.

Contraindications

Q-REstrain is contraindicated in the following situations due to potential risks or reduced efficacy:

• Large tumor burdens: Tumors over 5 cm in size (single or total).
• Compartmentalized or CNS cancers.
• Specific conditions or recent treatments:
  • Tumors in the lung or liver (due to risk of Tumor Lysis Syndrome).
  • Recent chemotherapy, radiation, radioactive seed therapy, Delta T cell therapy, or blood transfusions.
  • Patients with cachexia (wasting syndrome).
• Pregnancy and young children:
  • Contraindicated for children under 10 for cancer treatment.
  • Contraindicated for pathogen treatment in children under 4.

Key Benefits of Q-REstrain

1. Highly Targeted:
   • It focuses exclusively on the target cells or organisms, sparing healthy cells from damage.
2. Long-Lasting Impact:
   • A single dose provides up to six months of action, reducing the need for frequent treatments.
3. Effective Across Various Conditions:
   • Suitable for treating both cancers (in early stages or with small burdens) and specific pathogens.
4. Non-Immune-Based:
   • Unlike immunotherapies, Q-REstrain directly interferes with cellular processes, offering an alternative for patients not eligible for immune-based treatments.

Administration and Suitability

• Administered via intravenous infusion.
• Appropriate for patients with small cancer burdens or early-stage disease and those seeking pathogen-targeted therapy.

The QREstrain therapy represents a breakthrough in precision medicine, providing a targeted, effective solution for certain cancers, viruses, and pathogens. Leveraging cutting-edge RNA interference technology offers patients a powerful option for disease management with minimal impact on healthy cells.